H.C. Wainwright Starts Aerie Pharma (AERI) at Buy

September 20, 2016 8:41 AM EDT
Get Alerts AERI Hot Sheet
Price: $40.68 -0.9%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 17 | New: 10
Trade AERI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

H.C. Wainwright initiated coverage on Aerie Pharma (NASDAQ: AERI) with a Buy rating and a price target of $66. Analyst Corey Davis is bullish following Phase 3 results from Roclatan's MERCURY 1 study.

"We have long been believers in the Specialty Pharma business model ofselling drugs on their own given the leverage to earnings that comeswith fast growing revenue, a small and largely fixed cost base, longproduct cycles, and a small share base. Aerie has all of that, has now been majorly de-risked, and all of that comes in the context ofan attractive valuation. Now that the Phase 3 results from Roclatan'sMERCURY 1 study in glaucoma are as positive as we could have hoped, we can see the stock well on its way to our target as the market continues to better appreciate the drug's potential. The primary debate inthe investment community will continue to be how large these drugsc an be given the largely genericized market," said Davis.

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $34.12 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, New Coverage

Related Entities

Earnings, H.C. Wainwright

Add Your Comment